Yantai Dongcheng Pharmaceutical GroupLtd Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 1/6
Yantai Dongcheng Pharmaceutical GroupLtd's earnings have been declining at an average annual rate of -7%, while the Biotechs industry saw earnings growing at 5.9% annually. Revenues have been declining at an average rate of 0.1% per year. Yantai Dongcheng Pharmaceutical GroupLtd's return on equity is 1.2%, and it has net margins of 3.2%.
Anahtar bilgiler
-7.0%
Kazanç büyüme oranı
-7.5%
EPS büyüme oranı
| Biotechs Sektör Büyümesi | 11.3% |
| Gelir büyüme oranı | -0.1% |
| Özkaynak getirisi | 1.2% |
| Net Marj | 3.2% |
| Son Kazanç Güncellemesi | 30 Sep 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Gelir ve Gider Dağılımı
Yantai Dongcheng Pharmaceutical GroupLtd nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Sep 24 | 2,853 | 91 | 696 | 226 |
| 30 Jun 24 | 2,911 | 137 | 679 | 204 |
| 31 Mar 24 | 3,072 | 224 | 689 | 195 |
| 31 Dec 23 | 3,276 | 210 | 749 | 197 |
| 30 Sep 23 | 3,427 | 263 | 796 | 189 |
| 30 Jun 23 | 3,603 | 323 | 849 | 180 |
| 31 Mar 23 | 3,554 | 302 | 847 | 174 |
| 01 Jan 23 | 3,583 | 307 | 788 | 164 |
| 30 Sep 22 | 3,858 | 220 | 804 | 145 |
| 30 Jun 22 | 3,851 | 165 | 802 | 146 |
| 31 Mar 22 | 3,902 | 140 | 791 | 144 |
| 01 Jan 22 | 3,912 | 152 | 804 | 138 |
| 30 Sep 21 | 3,637 | 341 | 759 | 129 |
| 30 Jun 21 | 3,599 | 353 | 860 | 117 |
| 31 Mar 21 | 3,596 | 411 | 895 | 122 |
| 31 Dec 20 | 3,419 | 418 | 898 | 109 |
| 30 Sep 20 | 3,395 | 214 | 1,010 | 104 |
| 30 Jun 20 | 3,312 | 196 | 991 | 103 |
| 31 Mar 20 | 3,172 | 164 | 1,022 | 92 |
| 31 Dec 19 | 2,993 | 155 | 1,001 | 89 |
| 30 Sep 19 | 2,877 | 366 | 976 | 62 |
| 30 Jun 19 | 2,709 | 347 | 884 | 74 |
| 31 Mar 19 | 2,467 | 302 | 793 | 72 |
| 31 Dec 18 | 2,333 | 280 | 732 | 65 |
| 30 Sep 18 | 2,098 | 228 | 586 | 99 |
| 30 Jun 18 | 1,842 | 212 | 515 | 68 |
| 31 Mar 18 | 1,679 | 185 | 478 | 48 |
| 31 Dec 17 | 1,596 | 173 | 449 | 40 |
| 30 Sep 17 | 1,511 | 172 | 471 | 0 |
| 30 Jun 17 | 1,377 | 149 | 407 | 0 |
| 31 Mar 17 | 1,245 | 145 | 351 | 0 |
| 31 Dec 16 | 1,158 | 131 | 311 | 0 |
| 30 Sep 16 | 1,014 | 119 | 247 | 0 |
| 30 Jun 16 | 903 | 95 | 223 | 0 |
| 31 Mar 16 | 852 | 83 | 194 | 0 |
| 31 Dec 15 | 795 | 90 | 175 | 0 |
| 30 Sep 15 | 725 | 94 | 122 | 0 |
| 30 Jun 15 | 724 | 99 | 119 | 0 |
| 31 Mar 15 | 727 | 103 | 123 | 0 |
| 31 Dec 14 | 751 | 104 | 119 | 0 |
| 30 Sep 14 | 786 | 99 | 124 | 0 |
| 30 Jun 14 | 783 | 96 | 105 | 0 |
| 31 Mar 14 | 782 | 91 | 89 | 0 |
| 31 Dec 13 | 775 | 101 | 77 | 0 |
Kaliteli Kazançlar: 002675 has high quality earnings.
Büyüyen Kar Marjı: 002675's current net profit margins (3.2%) are lower than last year (7.7%).
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: 002675's earnings have declined by 7% per year over the past 5 years.
Büyüme Hızlandırma: 002675's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Kazançlar vs. Sektör: 002675 had negative earnings growth (-65.5%) over the past year, making it difficult to compare to the Biotechs industry average (0.08%).
Özkaynak Getirisi
Yüksek ROE: 002675's Return on Equity (1.2%) is considered low.